Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IXICO PLC Director's Dealing 2016

Feb 5, 2016

7723_dirs_2016-02-05_e2b20ccf-6b9a-46e0-a4b2-e1aafa518de2.html

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1592O

IXICO plc

05 February 2016

5 February 2016

IXICO plc Director's dealings

5 February 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that it was notified on 4 February 2016 that, on the same day, Professor Derek Hill, Chief Executive of the Company, purchased 10,000 Ordinary Shares of 1p each in IXICO at a price of 33.68p pence per Ordinary Share.  As a consequence of this share purchase, Professor Derek Hill is beneficially interested in 487,169 Ordinary Shares representing 1.84% of the Company's issued share capital.

Enquiries:

IXICO plc +44 20 3763 7499
Derek Hill, CEO
Susan Lowther, CFO
Peel Hunt LLP (Nominated Adviser and Broker) +44 20 7418 8900
James Steel / Oliver Jackson
Daniel Stewart & Company (Joint Broker) +44 207 776 6550
Martin Lampshire / David Coffman
FTI Consulting Limited (Investor Relations) +44 20 3727 1000
Simon Conway / Mo Noonan / Matthew Moss

Notes to Editors

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSKZLFBQLFLBBL